Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AA.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
AA.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
B.1.163NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
B.1.497NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
AA.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
C.14NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
AY.43.5 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
AA.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
AA.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
B.1.177.15NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
AA.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
AA.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
B.1.402NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
A.30NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
DL.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
BA.5.1.15NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
BF.41.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
BF.39NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
BA.2.3.20NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
BE.10NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
HK.13NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
AY.117 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-17128.2France
AY.46.3 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-17128.2France
GW.2SNIID WH-1 F24381R24873TCAAGACTCACTTTCTTCCAC2142.862436424384F-17130.7Japan
AY.112.3 (Delta)SNIID WH-1 F24381R24873TCAAGACTCACTTTCTTCCAC2142.862436424384F-17130.7Japan
HH.8EWon-ECACACAATCGATGCGCAGTA20502636526346R-17131.6South Korea
HG.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-17135.3Japan
XBB.1.5.56SChan-SCAAGCTATAACGCAGCCTGTA2147.622286922849R-17139.2China
GA.7.2NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-17139.9Singapore
JW.1ORF1abNIID WH-1 F509R854CTCGAACTGCACCTCATGG1957.89492510F-17147.9Japan
BF.39.1ORF1abNIID WH-1 F509R854CTCGAACTGCACCTCATGG1957.89492510F-17147.9Japan
D.3ORF1abNIID WH-1 F509R854CTCGAACTGCACCTCATGG1957.89492510F-17147.9Japan
AY.120.1 (Delta)ORF1abNIID WH-1 F509R854CTCGAACTGCACCTCATGG1957.89492510F-17147.9Japan
BE.10ORF1abNIID WH-1 F509R854CTCGAACTGCACCTCATGG1957.89492510F-17147.9Japan
B.1.623ORF1abCN-CDC-ORF1abACGATTGTGCATCAGCTGA1947.371346013442R-17161.5China
JN.1.61ORF1abCN-CDC-ORF1abACGATTGTGCATCAGCTGA1947.371346013442R-17161.5China
BQ.1.1.24ORF1abCN-CDC-ORF1abACGATTGTGCATCAGCTGA1947.371346013442R-17161.5China
HK.3.7ORF1abCN-CDC-ORF1abACGATTGTGCATCAGCTGA1947.371346013442R-17161.5China
HW.1.1ORF1abCN-CDC-ORF1abACGATTGTGCATCAGCTGA1947.371346013442R-17161.5China
XBB.1.16.16ORF1abCN-CDC-ORF1abACGATTGTGCATCAGCTGA1947.371346013442R-17161.5China
B.1.273ORF1abCN-CDC-ORF1abACGATTGTGCATCAGCTGA1947.371346013442R-17161.5China
B.1.415.1ORF1abCN-CDC-ORF1abACGATTGTGCATCAGCTGA1947.371346013442R-17161.5China
B.1.177.21ORF1abCN-CDC-ORF1abACGATTGTGCATCAGCTGA1947.371346013442R-17161.5China
AM.3ORF1abNIID WH-1 Seq F519R840ACCTCATGGTCATGTTATGG2045502521F-17162.5Japan
EE.4ORF1abNIID WH-1 Seq F519R840ACCTCATGGTCATGTTATGG2045502521F-17162.5Japan
EZ.1ECharité-EACAGGTACGTTAATAGTTAATAGCGT2634.622626926294F-17195.6Germany
BQ.1.1.43ECharité-EACAGGTACGTTAATAGTTAATAGCGT2634.622626926294F-17195.6Germany
BE.7ECharité-EACAGGTACGTTAATAGTTAATAGCGT2634.622626926294F-17195.6Germany
CM.9NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-17205US
KP.2.13NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-17205US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used